Multicenter Assessment of Treatment Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia (20180232) (Retrospective relapse/refractory AML outcomes)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/49921
• EU PAS number:
  EUPAS26165
• Study ID:
  49921
• Official title and acronym:
  Multicenter Assessment of Treatment Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia (20180232) (Retrospective relapse/refractory AML outcomes)
• DARWIN EU® study:
  No
• Study countries:
  Australia

  Korea, Republic of

  United States
• Study description:
  Study activities on 20180232 were canceled December 31, 2023. As study activities were canceled during data analysis, no final study results are available and study report will not be authored.
• Study status:
  Ongoing

Research institution and networks

Institutions

Amgen

United States

Contact details

Global Development Leader Amgen Inc.

Study contact

[e-mail]

Global Development Leader Amgen Inc.

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 31/12/2018

Actual: 31/03/2019

Data collection

Planned: 30/04/2019

Actual: 04/04/2019

Start date of data analysis

Planned: 01/07/2021

Actual: 14/11/2022

Date of final study report

Planned: 31/12/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable